全文获取类型
收费全文 | 1473篇 |
免费 | 161篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 44篇 |
妇产科学 | 42篇 |
基础医学 | 221篇 |
口腔科学 | 51篇 |
临床医学 | 163篇 |
内科学 | 248篇 |
皮肤病学 | 48篇 |
神经病学 | 125篇 |
特种医学 | 75篇 |
外科学 | 119篇 |
综合类 | 33篇 |
预防医学 | 240篇 |
眼科学 | 17篇 |
药学 | 98篇 |
中国医学 | 5篇 |
肿瘤学 | 106篇 |
出版年
2022年 | 9篇 |
2021年 | 26篇 |
2020年 | 25篇 |
2019年 | 18篇 |
2018年 | 31篇 |
2017年 | 38篇 |
2016年 | 30篇 |
2015年 | 21篇 |
2014年 | 37篇 |
2013年 | 64篇 |
2012年 | 69篇 |
2011年 | 75篇 |
2010年 | 35篇 |
2009年 | 36篇 |
2008年 | 61篇 |
2007年 | 64篇 |
2006年 | 55篇 |
2005年 | 78篇 |
2004年 | 57篇 |
2003年 | 55篇 |
2002年 | 51篇 |
2001年 | 46篇 |
2000年 | 39篇 |
1999年 | 36篇 |
1998年 | 25篇 |
1997年 | 27篇 |
1996年 | 21篇 |
1995年 | 19篇 |
1994年 | 24篇 |
1993年 | 18篇 |
1992年 | 34篇 |
1991年 | 30篇 |
1990年 | 18篇 |
1989年 | 29篇 |
1988年 | 26篇 |
1987年 | 24篇 |
1986年 | 21篇 |
1985年 | 22篇 |
1984年 | 19篇 |
1983年 | 19篇 |
1982年 | 11篇 |
1979年 | 18篇 |
1977年 | 8篇 |
1976年 | 10篇 |
1975年 | 12篇 |
1974年 | 8篇 |
1970年 | 9篇 |
1969年 | 8篇 |
1968年 | 12篇 |
1966年 | 9篇 |
排序方式: 共有1646条查询结果,搜索用时 15 毫秒
1.
2.
3.
D H Russell N E Zorn A R Buckley P D Crowe M D Sauro E M Hadden R V Farese H E Laird 《European journal of pharmacology》1990,188(2-3):139-152
Prolactin (PRL) and other trophic factors rapidly activate a nuclear pool(s) of protein kinase C (nPKC) in purified splenocyte nuclei. The PRL also enhanced [2-3H]glycerol incorporation into nuclear mono- and triacylglycerol. An assay was devised which not only probed the ability of the hormone to activate protein kinase C (PKC) but also demonstrated the presence of nuclear substrates. Using this methodology, a biphasic concentration-response curve to PRL was observed. Heterologous species of PRL and various growth factors also activated nPKC. The PRL-induced nPKC stimulation was antagonized by various immunomodulators, G protein-coupling inhibitors, PKC inhibitors, a calmodulin inhibitor, and a peripheral benzodiazepine agonist and antagonist. A monoclonal antibody to PKC, anti-rat PRL antiserum and a monoclonal anti-rat PRL receptor antibody antagonized PRL-induced PKC-dependent nuclear phosphorylation, further implicating nPKC and a PRL receptor-mediated activation process. Nuclear PKC may be a major target for trophic regulation in response to both positive and negative growth signals. 相似文献
4.
As knowledge of the human genome continues to grow, more progress is being made towards not only identifying the genes involved in disease susceptibility but also in defining the synergistic role genes play with environmental exposures. The detection of gene‐environment interactions is important as it can offer clinicians a potential means of intervention. The discovery of interactions relies heavily on powerful statistical methods. We present a test, FBAT‐I, that can be used to investigate gene‐environment interaction. The test uses the case‐parent triad design and protects the statistical inference from potential spurious results due to population admixture. 相似文献
5.
6.
7.
C. Laird Birmingham 《Canadian Medical Association journal》1994,150(8):1276-1277
8.
9.
Gerald L DeNardo Arutselvan Natarajan Saphon Hok Julie Perkins Monique Cosman Sally J DeNardo Felice C Lightstone Gary R Mirick Laird A Miers Rodney L Balhorn 《Journal of nuclear medicine》2007,48(8):1338-1347
Despite their large size, antibodies (Abs) are suitable carriers to deliver systemic radiotherapy, often molecular image-based, for lymphoma and leukemia. Lym-1 Ab has proven to be an effective radioisotope carrier, even in small amounts, for targeting human leukocyte antigen DR (HLA-DR), a surface membrane protein overexpressed on B-cell lymphoma. Pairs of molecules (referred to as ligands), shown by computational and experimental methods to bind to each of 2 sites within the Lym-1 epitopic region, have been linked to generate small (<2 kDa) molecules (referred to as selective high-affinity ligands [SHALs]) to mimic the targeting properties of Lym-1 Ab. METHODS: A lysine-polyethylene glycol (PEG) backbone was used to synthetically link 2 of the following ligands: deoxycholate, 5-leuenkephalin, triiodothyronine, thyronine, dabsyl-L-valine, and N-benzoyl-L-arginyl-4-amino-benzoic acid to generate a series of 13 bidentate SHALs with a biotin or 1,4,7,10-tetraazacyclododecane-N,N',N',N'-tetraacetic acid (DOTA) chelate attached to the linker. These SHALs have been assessed for their selectivity in binding to HLA-DR10-expressing cells and for their pharmacokinetics and tissue biodistribution in mice. Biotinylated versions of these SHALs discriminated cell lines positive for HLA-DR10 expression with near-nanomolar affinity. The DOTA versions of 4 SHALs were labeled with (111)In for pharmacokinetic studies in mice with HLA-DR10-expressing malignant Raji xenografts. RESULTS: The bidentate, biotinylated, and DOTA-SHALs were synthesized in high-purity, multimilligram amounts. Mean radiochemical and product yields and purities were 90%, 75%, and 90% at mean specific activities of 3.9 MBq/microg (105 microCi/microg) for the (111)In-labeled SHALs. As expected, rapid blood clearance and tumor targeting were observed. The pharmacokinetics of the SHALs was influenced by the component ligands. Biliary clearance, kidney localization, and serum receptor binding contributed to less favorable tumor targeting. CONCLUSION: A series of SHALs was readily synthesized in multimilligram amounts and showed the expected selective binding in vitro. Better selection of the SHAL components should provide second-generation SHALs with improved properties to fulfill the substantial potential of these novel molecular carriers for targeting. 相似文献